Anne Schaap-Nutt, Dane A. Thyssen, David W. Drell and Frank Entschladen Pages 6522 - 6528 ( 7 )
As the number of novel drugs that have entered the market in oncology has slowed in recent years, there has been a dramatic shift towards new therapeutic approaches. The majority of cancer patients die from metastasis formation, which has prompted the pharmaceutical industry to begin to investigate a new class of agents: anti-metastatics. This review provides an overview of the targets, mechanisms of action, and drug substances currently in the pharma pipeline to inhibit tumor cell migration and metastasis formation.
Metastasis, invasion, cell migration, signal transduction.
, , , MetaVi Labs Inc, 16238 Ranch Road 620 North, Suite F-347, Austin, Texas 78717, USA.